Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Multicenter, Single-Arm, Open-Label Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects With Active Psoriatic Arthritis

NCT03783026 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03783026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03783026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Multicenter, Single-Arm, Open-Label Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects With Active Psoriatic Arthritis
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Completed
Start date
February 6, 2019
Completion date
May 11, 2022
Enrollment
123 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis